Everolimus in the Treatment of Metastatic Breast Cancer
The discovery of the mammalian target of rapamycin (mTOR) molecular pathway has brought insight into its vital role in breast cancer pathogenesis. Several clinical trials have shown that the mTOR inhibitor everolimus could improve patient outcomes in several subtypes of breast cancer, including horm...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2015-01-01
|
| Series: | Breast Cancer: Basic and Clinical Research |
| Online Access: | https://doi.org/10.4137/BCBCR.S29268 |